JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 4, 2009, Pages 722-725

  Dentali, Francesco ^a   Squizzato, A ^a   Appio, L ^a   Brivio, L ^a   Ageno, W ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ARTERY THROMBOSIS; EMBASE; GENE FREQUENCY; GENE MUTATION; HUMAN; LETTER; MEDLINE; MYELOPROLIFERATIVE DISORDER; PREVALENCE; PRIORITY JOURNAL;

ARTERIAL OCCLUSIVE DISEASES; HUMANS; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PREVALENCE; THROMBOSIS;

EID: 63049100610     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03303.x     Document Type: Letter

References (13)

1. Gruppo Italiano Studio Policitemia. Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-64.
2. Austin SK, Lambert JR. The JAK2(V617F) mutation and thrombosis. Br J Haematol 2008; 143: 307-20.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90.
4. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, For GG, for Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 3 Measures of observer variability (kappa statistic). CMAJ 2004; 171: 1369-73.
5. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
6. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A. JAK2V617F mutation screening as part of the hypercoagulable work up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: Assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83: 457-9.
7. Séne D, Elalamy I, Ancri A, Cacoub P. JAK2V617F mutation is not associated with unexplained recurrent arterial and venous thrombosis. Thromb Res 2008; 122: 427-8.
8. McMahon C, Abu-Elmagd K, Bontempo FA, Kant JA, Swerdlow SH. JAK2V617F mutation in patients with catastrophic intra-abdominal thromboses. Am J Clin Pathol 2007; 127: 736-43.
9. Abel GA, DeAngelo DJ, Connors JM, Sholl LM, McCaffrey RP, Longtine JA. Clinical JAK2V617F mutation testing. Limited utility for general hospital patients with venous and arterial thromboses in common locations. Am J Hematol 2008; 83: 519-20.
10. Xavier SG, Gadelha T, Schaffel R, Britto L, Pimenta G, Ribeiro DD, Sabino Ade P, Pires V, Renault IZ, Spector N. Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis. Blood Coagul Fibrinolysis 2008; 19: 468-9.
11. Smalberg JH, De Maat MP, Leebeek FW. Absence of the JAK2V617F mutation in patients with arterial thrombosis without overt myeloproliferative disease. J Thromb Haemost 2008; 6: 1606-7.
12. Pardanani A, Lasho TL, Morice WG, Pruthi RK, Tefferi A. JAK2V617 is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorder. J Thromb Haemost 2007; 5: 1784-5.
13. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB, Fu X, Zhao ZJ. JAK2(V617F): Prevalence in a large Chinese hospital population. Blood 2007; 109: 339-42.